104P The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression after anti-PD-L1/PD-1 immunotherapy. Cadonilimab (AK104) is a bispecific antibody targeting PD-1 and CTLA-4 simultaneously. Here, we reported the efficacy and safety of cadonilimab with or without single-agent chemotherapy as a second- or later-line setting for metastatic NSCLC who developed disease progression after checkpoint inhibitor and chemotherapy.
Authors
- Zhi‐gang Yang (ORCID: https://orcid.org/0000-0001-9341-7697)
- Yan Li (ORCID: https://orcid.org/0000-0002-9447-7154)
- Meng‐Chih Lin (ORCID: https://orcid.org/0000-0001-7777-9356)
- Yuan Luo (ORCID: https://orcid.org/0000-0003-1198-3877)
- Tian Xia (ORCID: https://orcid.org/0000-0001-7385-7222)
- Rui Chen (ORCID: https://orcid.org/0000-0002-1587-0362)
- J. Li (ORCID: https://orcid.org/0000-0001-5245-2074)
- Gang Huang (ORCID: https://orcid.org/0000-0002-5457-5358)
- H. Chen (ORCID: https://orcid.org/0009-0005-6800-0909)
- Dan Yang (ORCID: https://orcid.org/0000-0001-9984-7225)
Institutions
- Guangdong Medical College (CN)
- Affiliated Hospital of Guangdong Medical College Hospital (CN)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100847
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00